IMAB

MKT CAP:$237M

I-Mab

Market Cap

$237M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.03+$3.12 (+344.81%)

Dec 29, 2025

Company Details

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous...

CEO

Xi-Yong Fu

IPO Date

Jan 17, 2020

Website

www.i-mabbiopharma.com

Key Metrics TTM

Revenue

-$36M

-115.1% YoY

Net Income

-$287M

EPS (Diluted)

-$3.63

Free Cash Flow

$0

Revenue / Share

-$0.45

Gross Margin

105.5%

Operating Margin

666.6%

Net Margin

793.2%

FCF Margin

0.0%

P/S

—

P/E

—

Earnings Reports

FY 2024

Apr 3, 2025

$0EPS -$0.65

Q1 2024

Mar 30, 2024

$0EPS -$0.12

Q4 2022

May 1, 2023

-$20M-489.2%EPS -$1.29

Q3 2022

Sep 29, 2022

-$20M-489.2%EPS -$1.29

Q2 2022

Nov 10, 2022

$4MEPS -$0.93

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 18	$2M	$2M	-$15M
Q2 18	$2M	$2M	-$15M
Q3 18	$3M	$3M	-$16M
Q4 18	$2M	$2M	-$18M
Q3 19	$2M	$2M	-$45M
Q1 20	$0	$0	-$45M
Q2 20	$0	$0	-$45M
Q3 20	$0	$0	-$58M
Q4 20	$225M	$225M	$170M
Q3 21	$5M	$2M	-$76M
Q4 21	$5M	$2M	-$76M
Q1 22	$4M	$2M	-$60M
Q2 22	$4M	$2M	-$60M
Q3 22	-$20M	-$20M	-$84M
Q4 22	-$20M	-$20M	-$84M
Q1 24	$0	$0	-$13M

Valuation

Quarter	P/S	P/E
Q1 18	—	—
Q2 18	—	—
Q3 18	—	—
Q4 18	92.2x	—
Q3 19	85.4x	—
Q1 20	95.6x	—
Q2 20	409.0x	—
Q3 20	1088.6x	—
Q4 20	13.3x	43.5x
Q3 21	23.8x	278.9x
Q4 21	16.4x	—
Q1 22	5.8x	—
Q2 22	53.2x	—
Q3 22	—	—
Q4 22	—	—
Q1 24	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 20	-$26M	-$26M
Q3 20	-$34M	-$35M
Q4 20	$148M	$148M
Q1 21	-$32M	-$33M
Q2 21	-$32M	-$33M
Q3 21	-$39M	-$41M
Q4 21	-$39M	-$41M
Q1 22	-$42M	-$43M
Q2 22	-$42M	-$43M
Q3 22	$0	$0
Q4 22	-$310M	-$315M
Q1 23	$0	$0
Q2 23	$0	$0
Q3 23	$0	$0
Q4 23	$0	$0
Q1 24	$0	$0

Capital Expenditures

Quarter	CapEx
Q2 20	$9.9K
Q3 20	$675.9K
Q4 20	$474.4K
Q1 21	$296.7K
Q2 21	$296.7K
Q3 21	$2M
Q4 21	$2M
Q1 22	$1M
Q2 22	$1M
Q3 22	$0
Q4 22	$6M
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 19	+40.3%	+190.4%
Q1 20	-100.0%	+177.2%
Q2 20	-100.0%	+128.8%
Q3 20	-100.0%	+188.9%
Q4 20	+10184.5%	+17.6%
Q3 21	—	+81.7%
Q4 21	—	+81.7%
Q1 22	—	+10.3%
Q2 22	-98.3%	+15.4%
Q3 22	-489.2%	-21.5%
Q4 22	-489.2%	-21.5%
Q1 24	-100.0%	-79.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 20	$17M	—
Q3 20	$24M	—
Q4 20	$15M	6.5%
Q1 21	$24M	—
Q2 21	$24M	—
Q3 21	$20M	389.9%
Q4 21	$20M	389.9%
Q1 22	$14M	379.8%
Q2 22	$14M	379.8%
Q3 22	$12M	—
Q4 22	$12M	—
Q1 23	$10M	—
Q2 23	$10M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	-$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 18	$15M	$1M
Q2 18	$15M	$1M
Q3 18	$16M	$3M
Q4 18	$16M	$4M
Q3 19	$46M	$1M
Q1 20	$32M	$13M
Q2 20	$32M	$13M
Q3 20	$37M	$20M
Q4 20	$42M	$13M
Q3 21	$45M	$33M
Q4 21	$45M	$33M
Q1 22	$33M	$29M
Q2 22	$33M	$29M
Q3 22	$33M	$31M
Q4 22	$33M	$31M
Q1 24	$6M	$8M

Revenue Segments

Quarter	Grant
Q3 20	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 21	$515M	$110M	$625M
Q4 21	$515M	$110M	$625M
Q1 22	$542M	$31M	$573M
Q2 22	$542M	$31M	$573M
Q3 22	$470M	$35M	$505M
Q4 22	$470M	$34M	$504M
Q1 23	$345M	$86M	$430M
Q2 23	$345M	$86M	$430M
Q3 23	$313M	$22M	$335M
Q4 23	$313M	$21M	$334M
Q1 24	$0	$0	$0
Q2 24	$22M	$59M	$81M
Q3 24	$12M	$15M	$27M
Q4 24	$68M	$105M	$173M
Q1 25	$54M	$115M	$169M
Q2 25	$165M	$210.0K	$166M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 18	58M	—	—
Q2 18	58M	0.0%	—
Q3 18	58M	0.0%	—
Q4 18	58M	0.0%	—
Q3 19	58M	0.0%	0.0%
Q1 20	53M	-9.0%	-9.0%
Q2 20	53M	0.0%	-9.0%
Q3 20	59M	+12.2%	+2.1%
Q4 20	71M	+19.3%	+21.9%
Q3 21	79M	+10.8%	+48.2%
Q4 21	79M	0.0%	+48.2%
Q1 22	82M	+4.6%	+38.2%
Q2 22	82M	0.0%	+15.8%
Q3 22	83M	+0.9%	+5.6%
Q4 22	83M	0.0%	+5.6%
Q1 24	81M	-2.4%	-1.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 18	—	—
Q2 18	—	—
Q3 18	—	—
Q4 18	—	—
Q3 19	—	—
Q1 20	$0	185
Q2 20	$0	185
Q3 20	$0	185
Q4 20	$988.6K	228
Q3 21	$22.5K	228
Q4 21	$13.6K	378
Q1 22	$10.0K	378
Q2 22	$10.0K	378
Q3 22	-$52.8K	378
Q4 22	-$62.8K	318
Q1 24	$0	220

Revenue / Employee